Adam Dubow - Day One General Counsel
| DAWN Stock | USD 13.34 0.28 2.06% |
Executive
Adam Dubow is General Counsel of Day One Biopharmaceuticals
| Age | 57 |
| Address | 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
| Phone | 650 484 0899 |
| Web | https://dayonebio.com |
Adam Dubow Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Dubow against Day One stock is an integral part of due diligence when investing in Day One. Adam Dubow insider activity provides valuable insight into whether Day One is net buyers or sellers over its current business cycle. Note, Day One insiders must abide by specific rules, including filing SEC forms every time they buy or sell Day One'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Dubow over six months ago Disposition of 3253 shares by Adam Dubow of Day One at 16.0787 subject to Rule 16b-3 |
Day One Management Efficiency
The company has return on total asset (ROA) of (0.2543) % which means that it has lost $0.2543 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1784) %, meaning that it created substantial loss on money invested by shareholders. Day One's management efficiency ratios could be used to measure how well Day One manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.62. At this time, Day One's Net Tangible Assets are very stable compared to the past year. As of the 21st of November 2024, Non Currrent Assets Other is likely to grow to about 263.7 K, while Total Assets are likely to drop about 239.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| JD Esq | Terns Pharmaceuticals | 55 | |
| Bryan JD | Eledon Pharmaceuticals | 44 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| John Herberger | Eledon Pharmaceuticals | N/A | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| MS MBA | PDS Biotechnology Corp | 58 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.25 |
Day One Biopharmaceu Leadership Team
Elected by the shareholders, the Day One's board of directors comprises two types of representatives: Day One inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Day. The board's role is to monitor Day One's management team and ensure that shareholders' interests are well served. Day One's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Day One's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD Chiodin, Chief Officer | ||
| Jaa Roberson, Chief Officer | ||
| Elly MD, Chief Officer | ||
| Adam Dubow, General Counsel | ||
| Lauren MBA, Chief Officer | ||
| Jeremy MBA, President CEO | ||
| Adam JD, General Officer | ||
| Mike Preigh, Chief Operations | ||
| Charles II, CFO COO | ||
| MBA II, CFO COO | ||
| John Stubenrauch, Chief Officer | ||
| Julie MBA, CoFounder Director | ||
| Prof MD, Chief Officer |
Day Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Day One a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.83) % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 817.76 M | ||||
| Shares Outstanding | 100.85 M | ||||
| Shares Owned By Insiders | 16.98 % | ||||
| Shares Owned By Institutions | 93.10 % | ||||
| Number Of Shares Shorted | 18.02 M | ||||
| Price To Earning | 3.88 X |
Pair Trading with Day One
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.Moving against Day Stock
| 0.37 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.33 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.32 | PALI | Palisade Bio | PairCorr |
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.